medRxiv Gets Played Again!
More preprint nonsense with commercial goals — with medRxiv's founder as ringleader
Sometimes, I just have to write these things down out of a sense of duty — yes, medRxiv has been played again by commercial entities seeking to use preprinting to promote corporate ends.
The first time was in 2020 by a connected thermometer company called Kinsa. They claimed a preprint would be posted in 48 hours showing how their thermometer data could predict Covid-19 hotspots up to two weeks earlier than the CDC. The preprint was finally posted 17 days later. It has never been published in a peer-reviewed journal.
The second time was in 2021, when Johnson & Johnson boasted a preprint on medRxiv would show better efficacy for its vaccines. No preprint ever showed up, and the New York Times was chagrined at how it was fooled.
The pathway from medRxiv to the New York Times seems well-trodden, perhaps because medRxiv has Yale University, Cold Spring Harbor Labs, and BMJ as its sponsors, so it seems like a safe bet for preprint clickbait. Coverage by the New York Times means success for companies’ “publication by press release” tactics.
Now, the same path — from medRxiv to the New York Times — has been exploited again, this time by another company pimping long-Covid treatments.
Also, this preprint is different — Harlan Krumholz of Yale, who heads up medRxiv — is one of the co-authors.
The ringmaster is now part of the show, I guess.